On October 30th, Tianjin Jin Yao Pharmaceutical Co., Ltd, a subsidiary of Tianjin Tianyao Pharmaceuticals Co.,Ltd., received the Notice of Approval for Drug Supplementary Application approved and issued by National Medical Products Administration for Magnesium Sulfate Injection, approving the drug to pass the consistency evaluation of generic drug quality and efficacy.

It is learned that magnesium sulfate injection is an anticonvulsant, which is mainly used for pregnancy-induced hypertension, lowering blood pressure and treating pre-eclampsia and eclampsia. In China, magnesium sulfate injection belongs to category A varieties of the National Insurance Medicine List in 2022 and also a variety on the national essential drug list, with a demand market of approximate 300 million yuan. According to the national enlarged hospital data of MENET (including urban public hospitals, county-level public hospitals, urban community hospitals and township hospitals), the domestic sales of magnesium sulfate injection in 2021 and 2022 were 280.12 million yuan and 281.59 million yuan respectively.

At present, Tianjin Tianyao Pharmaceuticals Co.,Ltd. has actively implemented the layout of the whole industrial chain of "APIs plus preparations" focusing on two core drugs: steroid hormones and amino acids. The qualification of the two drugs provided a new boost for the preparation business of Tianjin Tianyao Pharmaceuticals Co.,Ltd. in domestic market. According to the relevant national policies and regulations, drugs that have passed the consistency evaluation shall be provided with appropriate support in terms of medical insurance payment, and should be given priority in the procurement and selection by medical institutions. After the magnesium sulfate injection of Tianjin Tianyao Pharmaceuticals Co.,Ltd. passing the evaluation, the billion-dollar market share of this single product is expected to be further improved.

From this year, Tianjin Tianyao Pharmaceuticals Co.,Ltd. has made many breakthroughs in its preparation business segment. Among them, the Drug Registration Certificate for Diflucortolone valerate cream and terbutaline sulfate aerosol inhalation solution have successively been issued; The Notice of Approval for Drug Supplementary Application for the small-sized prednisone tablets has been issued; The Notice of Approval of Clinical Trials for umecium bromide veramentol inhalation powder aerosol and hydrocortisone sustained-release tablets have successively been issued; Diazepam injection, fluorouracil injection, mecobalamin injection and magnesium sulfate injection have passed the consistency evaluation of generic drug quality and efficacy. At present, Tianjin Tianyao Pharmaceuticals Co.,Ltd. is steadily promoting the competitiveness of preparation business, creating conditions for larger market space and higher market share of superior varieties.